Who are Stamaril™'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bacillus Calmette-Guerin (BCG), Yellow fever vaccine, Institut Pasteur, Attenuated Hepatitis A Vaccine, H2 Strain, RotaTeq™ (V260), Bacille Calmette Guerin (BCG), BCG Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/stamaril.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Stamaril™ — Competitive Intelligence Brief

Stamaril™ (Stamaril™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Yellow fever virus (17D strain) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Stamaril™ (Stamaril™) — GlaxoSmithKline. Stamaril is a live attenuated yellow fever vaccine that stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Stamaril™ TARGET	Stamaril™	GlaxoSmithKline	phase 3	Live attenuated vaccine	Yellow fever virus (17D strain)
Bacillus Calmette-Guerin (BCG)	Bacillus Calmette-Guerin (BCG)	Massachusetts General Hospital	marketed	Live attenuated vaccine / Immunotherapy
Yellow fever vaccine, Institut Pasteur	Yellow fever vaccine, Institut Pasteur	University of Oxford	marketed	Live attenuated vaccine
Attenuated Hepatitis A Vaccine, H2 Strain	Attenuated Hepatitis A Vaccine, H2 Strain	Jiangsu Province Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Hepatitis A virus
RotaTeq™ (V260)	RotaTeq™ (V260)	Merck Sharp & Dohme LLC	marketed	Live attenuated vaccine
Bacille Calmette Guerin (BCG)	Bacille Calmette Guerin (BCG)	Bandim Health Project	marketed	Live attenuated vaccine
BCG Solution	BCG Solution	Alliance for Clinical Trials in Oncology	marketed	Live attenuated vaccine / Immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Stamaril™ — Competitive Intelligence Brief. https://druglandscape.com/ci/stamaril. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab